Genes for bad backs

Affiliations

Comment

Christopher H Evans. Gene Ther. 2025 Mar.

. 2025 Mar;32(2):78-79.

doi: 10.1038/s41434-024-00506-5. Epub 2024 Nov 20.

¹ Musculoskeletal Gene Therapy Laboratory, Mayo Clinic, Rochester, MN, USA. Evans.christopher@mayo.edu.

No abstract available

Conflict of interest statement

Competing interests: The author is a cofounder of Genascence Corp., an arthritis gene therapy company.

PCRX-201, a novel IL-1Ra gene therapy treatment approach for low back pain resulting from intervertebral disc degeneration.
Snuggs JW, Senter RK, Whitt JP, Jackson JD, Le Maitre CL. Snuggs JW, et al. Gene Ther. 2025 Mar;32(2):93-105. doi: 10.1038/s41434-024-00504-7. Epub 2024 Nov 21. Gene Ther. 2025. PMID: 39572769 Free PMC article.

1. Kang JD, Georgescu HI, McIntyre-Larkin L, Stefanovic-Racic M, Evans CH. Herniated cervical intervertebral discs spontaneously produce matrix metalloproteinases, nitric oxide, interleukin-6, and prostaglandin E2. Spine (Philos Pa 1976). 1995;20:2373–8.
1. Kang JD, Georgescu HI, McIntyre-Larkin L, Stefanovic-Racic M, Donaldson WF, Evans CH. Herniated lumbar intervertebral discs spontaneously produce matrix metalloproteinases, nitric oxide, interleukin-6, and prostaglandin E2. Spine (Philos Pa 1976). 1996;21:271–7.
1. Evans C. Potential biologic therapies for the intervertebral disc. J Bone Jt Surg Am. 2006;88:95–98.
1. Phillips KL, Jordan-Mahy N, Nicklin MJ, Le Maitre CL. Interleukin-1 receptor antagonist deficient mice provide insights into pathogenesis of human intervertebral disc degeneration. Ann Rheum Dis. 2013;72:1860–7. - PubMed
1. Le Maitre CL, Hoyland JA, Freemont AJ. Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ zymographic and gene therapy study. Arthritis Res Ther. 2007;9:R83. - PubMed - PMC